{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:15:30Z","timestamp":1780568130443,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:00:00Z","timestamp":1637971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:00:00Z","timestamp":1637971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s10067-021-05979-y","type":"journal-article","created":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T05:03:29Z","timestamp":1637989409000},"page":"721-730","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Axial spondyloarthritis may protect against poor outcomes in COVID-19: propensity score matched analysis of 9766 patients from a nationwide multi-centric research network"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0636-3235","authenticated-orcid":false,"given":"Rahul","family":"Raiker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8790-9991","authenticated-orcid":false,"given":"Haig","family":"Pakhchanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3643-3989","authenticated-orcid":false,"given":"Chengappa","family":"Kavadichanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2753-2990","authenticated-orcid":false,"given":"Latika","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6311-8634","authenticated-orcid":false,"given":"Sinan","family":"Karde\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4631-311X","authenticated-orcid":false,"given":"Sakir","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,27]]},"reference":[{"key":"5979_CR1","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","volume":"79","author":"M Gianfrancesco","year":"2020","unstructured":"Gianfrancesco M, Hyrich KL, Al-Adely S et al (2020) Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 79:859\u2013866. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217871","journal-title":"Ann Rheum Dis"},{"key":"5979_CR2","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1016\/S2665-9913(20)30422-7","volume":"3","author":"A Jorge","year":"2021","unstructured":"Jorge A, D\u2019Silva KM, Cohen A et al (2021) Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study. The Lancet Rheumatology 3:e131\u2013e137. https:\/\/doi.org\/10.1016\/S2665-9913(20)30422-7","journal-title":"The Lancet Rheumatology"},{"key":"5979_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00296-020-04764-5","volume":"41","author":"S Ahmed","year":"2021","unstructured":"Ahmed S, Gasparyan AY, Zimba O (2021) Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic. Rheumatol Int 41:243\u2013256. https:\/\/doi.org\/10.1007\/s00296-020-04764-5","journal-title":"Rheumatol Int"},{"key":"5979_CR4","doi-asserted-by":"publisher","unstructured":"Pablos JL, Galindo M, Carmona L et al (2020) Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis. Published Online First. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218296","DOI":"10.1136\/annrheumdis-2020-218296"},{"key":"5979_CR5","doi-asserted-by":"publisher","unstructured":"Ferri C, Giuggioli D, Raimondo V et al (2020) COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series. Clin Rheumatol. Published Online First. https:\/\/doi.org\/10.1007\/s10067-020-05334-7","DOI":"10.1007\/s10067-020-05334-7"},{"key":"5979_CR6","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1136\/annrheumdis-2020-217362","volume":"79","author":"P-M Duret","year":"2020","unstructured":"Duret P-M, Sebbag E, Mallick A et al (2020) Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. Ann Rheum Dis 79:1251\u20131252. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217362","journal-title":"Ann Rheum Dis"},{"key":"5979_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00296-020-04635-z","volume":"2020","author":"I Coskun Benlidayi","year":"2019","unstructured":"Coskun Benlidayi I, Kurtaran B, Tirasci E, Coronavirus disease, et al (2019) (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review. Rheumatol Int 2020:1\u201310. https:\/\/doi.org\/10.1007\/s00296-020-04635-z","journal-title":"Rheumatol Int"},{"key":"5979_CR8","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1007\/s10067-020-05073-9","volume":"39","author":"DP Misra","year":"2020","unstructured":"Misra DP, Agarwal V, Gasparyan AY et al (2020) Rheumatologists\u2019 perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol 39:2055\u20132062. https:\/\/doi.org\/10.1007\/s10067-020-05073-9","journal-title":"Clin Rheumatol"},{"key":"5979_CR9","doi-asserted-by":"publisher","unstructured":"RECOVERY Collaborative Group, Horby P, Lim WS et al (2020) Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med. Published Online First. https:\/\/doi.org\/10.1056\/NEJMoa2021436","DOI":"10.1056\/NEJMoa2021436"},{"key":"5979_CR10","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0140-6736(20)30858-8","volume":"395","author":"M Feldmann","year":"2020","unstructured":"Feldmann M, Maini RN, Woody JN et al (2020) Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet 395:1407\u20131409. https:\/\/doi.org\/10.1016\/S0140-6736(20)30858-8","journal-title":"Lancet"},{"key":"5979_CR11","doi-asserted-by":"publisher","first-page":"e653","DOI":"10.1016\/S2665-9913(20)30309-X","volume":"2","author":"PC Robinson","year":"2020","unstructured":"Robinson PC, Richards D, Tanner HL et al (2020) Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment. Lancet Rheumatol 2:e653\u2013e655. https:\/\/doi.org\/10.1016\/S2665-9913(20)30309-X","journal-title":"Lancet Rheumatol"},{"key":"5979_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.medj.2020.11.005","volume":"1","author":"PC Robinson","year":"2020","unstructured":"Robinson PC, Liew DFL, Liew JW et al (2020) The potential for repurposing anti-TNF as a Therapy for the treatment of COVID-19. Med (N Y) 1:90\u2013102. https:\/\/doi.org\/10.1016\/j.medj.2020.11.005","journal-title":"Med (N Y)"},{"key":"5979_CR13","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1053\/j.gastro.2020.08.028","volume":"159","author":"S Singh","year":"2020","unstructured":"Singh S, Bilal M, Pakhchanian H et al (2020) Impact of obesity on outcomes of patients with coronavirus disease 2019 in the United States: a multicenter electronic health records network study. Gastroenterology 159:2221-2225.e6. https:\/\/doi.org\/10.1053\/j.gastro.2020.08.028","journal-title":"Gastroenterology"},{"key":"5979_CR14","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/art.41619","volume":"73","author":"KM D\u2019Silva","year":"2021","unstructured":"D\u2019Silva KM, Jorge A, Cohen A et al (2021) COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: a US multicenter, comparative cohort study. Arthritis Rheumatol 73:914\u2013920. https:\/\/doi.org\/10.1002\/art.41619","journal-title":"Arthritis Rheumatol"},{"key":"5979_CR15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.2215\/CJN.13820820","volume":"16","author":"H Pakhchanian","year":"2021","unstructured":"Pakhchanian H, Raiker R, Mukherjee A et al (2021) Outcomes of COVID-19 in CKD patients: a multicenter electronic medical record cohort study. Clin J Am Soc Nephrol 16:785\u2013786. https:\/\/doi.org\/10.2215\/CJN.13820820","journal-title":"Clin J Am Soc Nephrol"},{"key":"5979_CR16","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s00296-020-04629-x","volume":"40","author":"E Kastritis","year":"2020","unstructured":"Kastritis E, Kitas GD, Vassilopoulos D et al (2020) Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes. Rheumatol Int 40:1353\u20131360. https:\/\/doi.org\/10.1007\/s00296-020-04629-x","journal-title":"Rheumatol Int"},{"key":"5979_CR17","doi-asserted-by":"publisher","unstructured":"Nu\u00f1o L, Navarro MN, Bonilla G et al (2020) Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases. Annals of the Rheumatic Diseases. Published Online First. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218054","DOI":"10.1136\/annrheumdis-2020-218054"},{"key":"5979_CR18","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/art.41567","volume":"73","author":"MA Gianfrancesco","year":"2021","unstructured":"Gianfrancesco MA, Leykina LA, Izadi Z et al (2021) Association of race and ethnicity with COVID-19 outcomes in rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician registry. Arthritis Rheumatol 73:374\u2013380. https:\/\/doi.org\/10.1002\/art.41567","journal-title":"Arthritis Rheumatol"},{"key":"5979_CR19","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1007\/s10067-020-05275-1","volume":"39","author":"S Ahmed","year":"2020","unstructured":"Ahmed S, Zimba O, Gasparyan AY (2020) Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow\u2019s triad. Clin Rheumatol 39:2529\u20132543. https:\/\/doi.org\/10.1007\/s10067-020-05275-1","journal-title":"Clin Rheumatol"},{"key":"5979_CR20","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2018-214388","volume":"78","author":"JA Avi\u00f1a-Zubieta","year":"2019","unstructured":"Avi\u00f1a-Zubieta JA, Chan J, De Vera M et al (2019) Risk of venous thromboembolism in ankylosing spondylitis: a general population-based study. Ann Rheum Dis 78:480\u2013485. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214388","journal-title":"Ann Rheum Dis"},{"key":"5979_CR21","doi-asserted-by":"publisher","first-page":"642","DOI":"10.4103\/0970-2113.192862","volume":"33","author":"P Ungprasert","year":"2016","unstructured":"Ungprasert P, Srivali N, Kittanamongkolchai W (2016) Ankylosing spondylitis and risk of venous thromboembolism: a systematic review and meta-analysis. Lung India 33:642\u2013645. https:\/\/doi.org\/10.4103\/0970-2113.192862","journal-title":"Lung India"},{"key":"5979_CR22","doi-asserted-by":"publisher","unstructured":"Goulielmos GN, Zervou MI (2021) Risk of venous thromboembolism in ankylosing spondylitis and rheumatoid arthritis: genetic aspects. J Rheum. Published Online First. https:\/\/doi.org\/10.3899\/jrheum.210131","DOI":"10.3899\/jrheum.210131"},{"key":"5979_CR23","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.semarthrit.2021.08.010","volume":"51","author":"R Raiker","year":"2021","unstructured":"Raiker R, DeYoung C, Pakhchanian H et al (2021) Outcomes of COVID-19 in patients with rheumatoid arthritis: a multicenter research network study in the United States. Semin Arthritis Rheum 51:1057\u20131066. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.08.010","journal-title":"Semin Arthritis Rheum"},{"key":"5979_CR24","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1161\/ATVBAHA.118.311660","volume":"38","author":"P Saha","year":"2018","unstructured":"Saha P, Smith A (2018) TNF-\u03b1 (tumor necrosis factor-\u03b1). Arterioscler Thromb Vasc Biol 38:2542\u20132543. https:\/\/doi.org\/10.1161\/ATVBAHA.118.311660","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5979_CR25","doi-asserted-by":"publisher","first-page":"32188","DOI":"10.1038\/srep32188","volume":"6","author":"J Bester","year":"2016","unstructured":"Bester J, Pretorius E (2016) Effects of IL-1\u03b2, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity. Sci Rep 6:32188. https:\/\/doi.org\/10.1038\/srep32188","journal-title":"Sci Rep"},{"key":"5979_CR26","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.gastro.2020.05.032","volume":"159","author":"EJ Brenner","year":"2020","unstructured":"Brenner EJ, Ungaro RC, Gearry RB et al (2020) Corticosteroids, but not tnf antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology 159:481-491.e3. https:\/\/doi.org\/10.1053\/j.gastro.2020.05.032","journal-title":"Gastroenterology"},{"key":"5979_CR27","doi-asserted-by":"publisher","unstructured":"Kridin K, Schonmann Y, Damiani G et al (2021) Tumor necrosis factor inhibitors are associated with a decreased risk of COVID-19-associated hospitalization in patients with psoriasis- A population-based cohort study. Dermatol Ther. e15003. https:\/\/doi.org\/10.1111\/dth.15003","DOI":"10.1111\/dth.15003"},{"key":"5979_CR28","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1053\/j.gastro.2020.05.065","volume":"159","author":"N Khan","year":"2020","unstructured":"Khan N, Patel D, Xie D et al (2020) Impact of anti-tumor necrosis factor and thiopurine medications on the development of COVID-19 in patients with inflammatory bowel disease: a nationwide Veterans Administration cohort study. Gastroenterology 159:1545-1546.e1. https:\/\/doi.org\/10.1053\/j.gastro.2020.05.065","journal-title":"Gastroenterology"},{"key":"5979_CR29","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1136\/annrheumdis-2020-218580","volume":"80","author":"KL Winthrop","year":"2021","unstructured":"Winthrop KL, Brunton AE, Beekmann S et al (2021) SARS CoV-2 infection among patients using immunomodulatory therapies. Ann Rheum Dis 80:269\u2013271. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218580","journal-title":"Ann Rheum Dis"},{"key":"5979_CR30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaad.2020.09.009","volume":"84","author":"A Yousaf","year":"2021","unstructured":"Yousaf A, Gayam S, Feldman S et al (2021) Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors or methotrexate: a multicenter research network study. J Am Acad Dermatol 84:70\u201375. https:\/\/doi.org\/10.1016\/j.jaad.2020.09.009","journal-title":"J Am Acad Dermatol"},{"key":"5979_CR31","doi-asserted-by":"publisher","unstructured":"Wong AY, MacKenna B, Morton CE et al (2021) Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Ann Rheum Dis. Published Online First. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219517","DOI":"10.1136\/annrheumdis-2020-219517"},{"key":"5979_CR32","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/cei.13020","volume":"190","author":"C Vitulano","year":"2017","unstructured":"Vitulano C, Tedeschi V, Paladini F et al (2017) The interplay between HLA-B27 and ERAP1\/ERAP2 aminopeptidases: from anti-viral protection to spondyloarthritis. Clin Exp Immunol 190:281\u2013290. https:\/\/doi.org\/10.1111\/cei.13020","journal-title":"Clin Exp Immunol"},{"key":"5979_CR33","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/tan.13305","volume":"92","author":"CM Gambino","year":"2018","unstructured":"Gambino CM, Aiello A, Accardi G et al (2018) Autoimmune diseases and 8.1 ancestral haplotype: an update. HLA 92:137\u201343. https:\/\/doi.org\/10.1111\/tan.13305","journal-title":"HLA"},{"key":"5979_CR34","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1136\/annrheumdis-2018-214612","volume":"78","author":"S Ahmed","year":"2019","unstructured":"Ahmed S (2019) Metering the METEOR in methotrexate failure: is propensity score a falling star? Ann Rheum Dis 78:e131\u2013e131. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214612","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05979-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05979-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05979-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T03:12:01Z","timestamp":1645758721000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05979-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,27]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["5979"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05979-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,27]]},"assertion":[{"value":"17 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SA has received honorarium as speaker for Pfizer (unrelated to the current study) and has no other potential conflicts of interest. SK has received congress travel, accommodation, and participation fee support (12th Anatolian Rheumatology Days) from AbbVie. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}